JP2017524742A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524742A5
JP2017524742A5 JP2017528754A JP2017528754A JP2017524742A5 JP 2017524742 A5 JP2017524742 A5 JP 2017524742A5 JP 2017528754 A JP2017528754 A JP 2017528754A JP 2017528754 A JP2017528754 A JP 2017528754A JP 2017524742 A5 JP2017524742 A5 JP 2017524742A5
Authority
JP
Japan
Prior art keywords
formula
compound
acid
alkyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524742A (ja
JP6670310B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2015/050555 external-priority patent/WO2016024858A1/en
Publication of JP2017524742A publication Critical patent/JP2017524742A/ja
Publication of JP2017524742A5 publication Critical patent/JP2017524742A5/ja
Application granted granted Critical
Publication of JP6670310B2 publication Critical patent/JP6670310B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528754A 2014-08-12 2015-07-29 テトラヒドロキノリン誘導体の調製のための合成中間体の調製方法 Active JP6670310B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12
NLPCT/NL2014/050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Publications (3)

Publication Number Publication Date
JP2017524742A JP2017524742A (ja) 2017-08-31
JP2017524742A5 true JP2017524742A5 (enExample) 2018-09-06
JP6670310B2 JP6670310B2 (ja) 2020-03-18

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528754A Active JP6670310B2 (ja) 2014-08-12 2015-07-29 テトラヒドロキノリン誘導体の調製のための合成中間体の調製方法

Country Status (27)

Country Link
US (1) US10112904B2 (enExample)
EP (2) EP4083022A1 (enExample)
JP (1) JP6670310B2 (enExample)
KR (1) KR102572626B1 (enExample)
CN (1) CN107108558B (enExample)
AR (1) AR101509A1 (enExample)
AU (1) AU2015302407B2 (enExample)
BR (1) BR112017002873B1 (enExample)
CA (1) CA2958040C (enExample)
CL (1) CL2017000367A1 (enExample)
DK (1) DK3180314T3 (enExample)
EA (1) EA034357B1 (enExample)
ES (1) ES2926775T3 (enExample)
HR (1) HRP20221061T1 (enExample)
HU (1) HUE059947T2 (enExample)
IL (1) IL250525B (enExample)
LT (1) LT3180314T (enExample)
MA (1) MA40378B1 (enExample)
MX (1) MX367908B (enExample)
PL (1) PL3180314T3 (enExample)
PT (1) PT3180314T (enExample)
RS (1) RS63575B1 (enExample)
SG (1) SG11201701077XA (enExample)
SI (1) SI3180314T1 (enExample)
SM (1) SMT202200385T1 (enExample)
TW (1) TWI691490B (enExample)
WO (1) WO2016024858A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513155A (ja) 2021-03-05 2024-03-22 ニューアムステルダム・ファルマ・ベー・フェー 認知症の治療のためのオビセトラピブ
AU2022320869A1 (en) 2021-07-26 2024-02-01 Newamsterdam Pharma B.V. Treatment of his hyporesponders
CA3242880A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. COMBINATION OF OBITECRAPIB AND SGLT2 INHIBITOR
TW202409008A (zh) 2022-07-05 2024-03-01 荷蘭商新阿姆斯特丹製藥公司 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體
TW202416994A (zh) 2022-08-22 2024-05-01 荷蘭商新阿姆斯特丹製藥公司 固定劑量醫藥組合物及其用途
EP4661865A1 (en) 2023-02-07 2025-12-17 NewAmsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025093436A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
WO2025146262A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
YU84303A (sh) * 2001-04-30 2006-05-25 Pfizer Products Inc. Postupak dobijanja cetp inhibitora
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
UY30244A1 (es) * 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法

Similar Documents

Publication Publication Date Title
JP2017524742A5 (enExample)
JP2018529687A5 (enExample)
RU2015103694A (ru) Способы синтеза спиро-оксиндольных соединений
HRP20221061T1 (hr) Postupak za pripremu sintetičkih intermedijera za pripremu tetrahidrokinolinskih derivata
JP2012515142A5 (enExample)
JP2015063536A5 (enExample)
JP2014500861A5 (enExample)
RU2016135762A (ru) Способ получения (r)-1,1,3-триметил-4-аминоиндана
JP2013533291A5 (enExample)
JP2021503464A5 (ja) レチノイドx受容体特異的なレチノイドの調製のための合成方法
JP2014507414A5 (enExample)
JP2016523246A5 (enExample)
JP5451870B2 (ja) 光学的に純粋なアミノ酸を得る方法
JP2020502244A5 (enExample)
JP2016516744A5 (enExample)
RU2018130270A (ru) Способ получения 4-алкокси-3-ацетоксипиколиновых кислот
JP2009221198A5 (enExample)
JP2014520075A5 (enExample)
US20180134660A1 (en) Process for the enantiomeric resolution of apremilast intermediates
JP2020502077A5 (enExample)
JP2017516808A5 (enExample)
JP2017509581A5 (enExample)
JP2017533926A5 (enExample)
JP2015508069A5 (enExample)
JP2005247850A5 (enExample)